ARID1B is emerging as a potential therapeutic target because of its pivotal role in chromatin remodeling and its elevated levels in breast cancer, which typically indicate a worse prognosis.[13, 16, 19, 21, 22, 23, 25, 26, 27] Thus, targeting ARID1B nuclear translocation could potentially hinder the survival and proliferation of cancer cells. The gene discussed is ARID1B; the disease is breast carcinoma.